Front Page › Markets & Main Street › From Wall Street

Medtronic (MDT) MiniMed split-off: is the capped odd-lot exchange still worth it?

Medtronic's MiniMed split-off promised a 7% discount, but the exchange ratio hit its cap. Here is the case for and against the odd-lot trade before the offer expires Oct. 9.

By MCAFax · Published October 9, 2026

A brass balance scale on a wood desk has its rising pan blocked from tilting further by an iron bar clamped above it. — Market Calls, Investigated · Markets & Main Street

Medtronic (NYSE: MDT) is splitting off its diabetes business, MiniMed Group (Nasdaq: MMED), through an exchange offer that lets Medtronic holders swap MDT shares for MMED shares at a 7% discount, and holders of fewer than 100 shares can skip proration. The catch is that the exchange ratio hit its cap of 4.5939 MiniMed shares per Medtronic share, so on the final pricing averages the headline 7.53% uplift shrank to about 3.7%. The offer expires at 12:00 midnight New York time at the end of Oct. 9, 2026 (11 p.m. CT), unless extended.

This is journalism and commentary, not investment advice. We hold no position unless stated.

How does the MDT-MiniMed exchange offer work?

MiniMed went public in March 2026 at $20.00 a share, and Medtronic kept about 90% of it. On Sept. 14, 2026, Medtronic launched an offer to exchange up to 225,361,295 MiniMed shares, about 80.1% of the company, for Medtronic ordinary shares. If the offer is oversubscribed, Medtronic says it intends to exchange its remaining 27,452,053 MiniMed shares as well, without extending the offer.

The pricing formula promised about $107.53 of MiniMed stock for every $100 of Medtronic stock tendered, based on the average daily volume-weighted prices (VWAPs) of both stocks over Oct. 5, 6 and 7. That works out to a 7% discount on MiniMed. But the formula had an upper limit of 4.5939 MiniMed shares per Medtronic share, and the offer terms warn that if the cap applies, tendering holders may receive less than $107.53, possibly much less.

That is what happened. On Oct. 7, Medtronic said the final calculated values would have produced a ratio above the cap, so the final ratio was set at 4.5939. The final averages were $86.9672 for Medtronic and $19.6268 for MiniMed, according to the information agent, D.F. King. At those numbers, 4.5939 MiniMed shares were worth about $90.16 for each Medtronic share, roughly a 3.7% premium, not 7.53%.

If the offer is oversubscribed, Medtronic says it would accept about 55,032,401 Medtronic shares if it also hands over its remaining stake, or about 49,056,639 if it does not. Tenders beyond that are prorated. Holders of fewer than 100 Medtronic shares who tender all of them are not prorated. That odd-lot rule is what drew special-situations investors in.

Is the MDT-MiniMed odd-lot trade a good bet right now?

It depends on what you think a 3-4% spread is worth for a few days of MiniMed price risk. Colin King (@valuedontlie), who writes about special situations, flagged the setup on Sept. 22 with a simple pitch: "Own shares of MDT and swap for MMED at 7% discount". He estimated then that at a Medtronic price of $90 or more, a 99-share odd lot would make "$600+" in a few weeks. By Oct. 5 he was more measured: "this odd lot spread narrowed a bunch..."

The math explains why. D.F. King's daily table shows the indicative ratio reached the 4.5939 cap on Sept. 22, the same day as his post, and stayed there. MiniMed then slid faster than Medtronic. MiniMed's daily VWAP was $21.9057 on Sept. 14 and its close was $19.80 on Oct. 8, just under its $20.00 IPO price. Medtronic's VWAP went from $93.6194 to an Oct. 8 close of $87.75.

At the Oct. 8 closes, 99 Medtronic shares cost about $8,687 and would convert into about 454.8 MiniMed shares worth about $9,005. That is a gap of roughly $318, about 3.7%, before trading costs, fractional-share handling and any move in MiniMed before the new shares arrive.

What's the bull case for the MDT exchange offer?

The bull case is that the cap shrank the spread but did not erase it, and an odd lot removes the biggest unknown, proration. Rod Alzmann (@RodAlzmann), a private investor who focuses on special situations, put the capped return at "about 3.5% at spot prices on a tendered odd lot" on Oct. 6. He called it less rich than past split-offs but "on a risk adjusted basis a worthwhile trade".

Supporters see a few days of exposure for a low-single-digit spread as a typical split-off setup. Medtronic also says the exchange is expected to be generally tax-free for U.S. federal income tax purposes, and the deal terms are fixed now that the ratio is final.

What's the bear case?

The bear case is that the discount was the whole point, and the cap took about half of it away. The Stock Spinoffs account (@stockspinoffs) noted on Oct. 5 that at the prior Friday's indicative values "the effective value advantage was about 4%", far below the headline. Barron's ran an Oct. 2 piece headlined "Why Medtronic's $4 Billion MiniMed Exchange Offer Is Losing Its Allure". Replying to it, @thetatraderx was blunter: "Arbs are the only ones getting paid here."

There are practical risks too:

MiniMed price risk. Tendering holders end up owning MiniMed, a newly separated insulin-delivery company trading below its IPO price. Any drop before and after delivery comes out of the spread.
Supply. Up to about 252.8 million MiniMed shares are going to Medtronic holders. Those who only wanted the discount may sell.
Hedging is crowded. Investors who want to lock in the spread by shorting MiniMed need to borrow it, and Alzmann described MiniMed as "scarce" to hedge.
Timing. Brokers often set their own tender cutoffs before the official deadline, and larger holders above 99 shares face proration if the offer is oversubscribed.

What would prove it right or wrong?

The dates are close. The offer and withdrawal rights expire at 12:00 midnight New York time at the end of Oct. 9, 2026, unless Medtronic extends or ends it. The tender count, and any proration, will be known only after the offer expires.

The odd-lot thesis looks right if the offer closes on schedule and MiniMed holds near its Oct. 8 close of $19.80 when the shares are delivered. It looks wrong if MiniMed falls more than about 3.7% from there, which would wipe out the spread. For larger tenders, a high proration factor would leave holders with more Medtronic stock than planned. If fewer than 80.1% of MiniMed shares are exchanged, Medtronic says it intends to complete a spin-off on the same day the offer closes.

This is journalism and commentary, not investment advice. We hold no position unless stated.

Sources:

Questions readers actually ask

What is the Medtronic MiniMed exchange offer?

It is a split-off in which Medtronic (MDT) lets its shareholders swap Medtronic shares for shares of MiniMed Group (MMED), its former diabetes business. Medtronic is offering up to 225,361,295 MiniMed shares, about 80.1% of the company, and may add its remaining 27,452,053 shares if the offer is oversubscribed.

What is the final exchange ratio for MDT to MMED?

Medtronic set the final ratio at 4.5939 MiniMed shares per Medtronic share on Oct. 7, 2026. That was the offer's upper limit, because the pricing formula would otherwise have produced a higher ratio. At the final averages of $86.9672 for Medtronic and $19.6268 for MiniMed, the cap worked out to about a 3.7% premium instead of the headline 7.53%.

When does the Medtronic exchange offer expire?

The offer and withdrawal rights expire at 12:00 midnight New York time at the end of Oct. 9, 2026, which is 11 p.m. CT, unless Medtronic extends or ends it. Brokers may set earlier internal cutoffs for tender instructions.

What is the odd-lot provision in the MDT split-off?

Shareholders who own fewer than 100 Medtronic shares and tender all of them are not subject to proration if the offer is oversubscribed. Larger holders may have only part of their tender accepted, so they could end up holding more Medtronic stock than they planned.

What are the risks of tendering MDT shares for MiniMed?

Tendering holders end up owning MiniMed, which closed at $19.80 on Oct. 8, 2026, just below its $20.00 IPO price. A drop of more than about 3.7% in MiniMed would erase the spread, and large tenders face proration. Hedging by shorting MiniMed depends on being able to borrow the shares.

Getting the calls? Shut it down.

MCAFax was built to do the thing you can't do from inside the room: make the phone stop. Check any broker against our member-built database, send cease & desist letters from your own Gmail, and build the paper trail. Some laws, like the TCPA, put statutory damages on illegal calls — whether they apply to your calls depends on your situation, and business lines get less protection than home ones. It's free, and we're not a law firm.

Join the network